FFS from 1 year after the onset of treatment according to the different combinations of β2-M at presentation (normal vhigh) and molecular response within the first year (Respondersv Nonresponders). Patients included were the same as in Fig 3. Three possible combinations were plotted: (A) normal β2-M and molecular responders, (B) either high β2-M and molecular responders or normal β2-M and molecular nonresponders, and (C) high β2-M and molecular nonresponders. Landmark: 12 months; P < .0001.